A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Objective Response Rate (ORR) assessed by blinded independent central review (BICR)

ORR is defined as the percentage of participants with a confirmed Complete Response or Partial Response (PR) per investigator review according to response evaluation criteria in solid tumors (RECIST) version 1.1.

Time frame: Up to Approximately 60 Months

Change from baseline at Week 12 in physical functioning as measured by the EORTC QLQ-C30

The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales, 3 symptom scales, a global health status/QoL scale, and 6 single items. Participants rate items on a 4-point scale ranging from 1 (not at all) to 4 (very much).

Time frame: Up to Approximately 12 weeks

Change from baseline at Week 12 in GHS/QoL as measured by the EORTC QLQ-C30.

Health-related quality-of-life and symptoms will be assessed with the EORTC QLQ-C30, version 3.0. The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a GHS/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4 point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

Time frame: Up to Approximately 12 Weeks

Duration Of Response (DoR) assessed by Blinded Independent Central Review (BICR)

Duration Of Response (DoR) defined as time from the first documented Complete Response (CR) or Partial Response (PR) to the first occurrence of radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first. DoR is defined for subjects with confirmed CR/PR.

Time frame: Up to Approximately 60 months

Disease Control Rate (DCR) assessed by Blinded Independent Central Review (BICR)

Disease Control Rate (DCR) is defined as best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) or Stable Disease (SD) based on Response Evaluation Criteria in Solid Tumors (RECIST) version1.1

Time frame: Up to Approximately 60 Months

Time To Response (TTR) assessed by Blinded Independent Central Review (BICR)

Time To Response (TTR) is defined as the number of months from the date of first dose to the date of best overall response of Complete Response (CR) or Partial Response (PR)

Time frame: Up to Approximately 60 months

Progression-Free Survival (PFS) assessed by the investigator

Progression-Free Survival (PFS) is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier.

Time frame: Up to Approximately 60 Months

Objective Response Rate (ORR) assessed by the investigator

Objective Response Rate (ORR) is defined as the percentage of participants with a confirmed Complete Response or Partial Response (PR) per investigator review according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

Time frame: Up to Approximately 60 Months

Duration Of Response (DoR) assessed by the investigator

Duration Of Response (DoR) defined as time from the first documented Complete Response (CR) or Partial Response (PR) to the first occurrence of radiographic progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first. DoR is defined for subjects with confirmed CR/PR.

Time frame: Up to Approximately 24 months

DCR assessed by the investigator

Disease Control Rate (DCR) is defined as best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) or Stable Disease (SD) based on Response Evaluation Criteria in Solid Tumors (RECIST) version1.1

Time frame: Up to Approximately 60 Months

TTR assessed by the investigator

Time To Response (TTR) is defined as the number of months from the date of first dose to the date of best overall response of Complete Response (CR) or Partial Response (PR)

Time frame: Up to Approximately 60 months

Change from baseline at Week 12 in the coughing item as measured by the EORTC QLQ-LC13.

The EORTC QLQ-LC13 is a lung cancer specific module and consists of 13 questions assessing lung cancer-associated symptoms and treatment-related effects, including one multiple-item scale to assess dyspnea and a series of single items assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain, and pain medication. Each item is assessed on a Likert scale from 1 (not at all) to 4 (very much).

Time frame: Up to Approximately 12 Weeks

Change from baseline at Week 12 in the pain in chest item as measured by the EORTC QLQLC13

The EORTC QLQ-LC13 is a lung cancer specific module and consists of 13 questions assessing lung cancer-associated symptoms and treatment-related effects, including one multiple-item scale to assess dyspnea and a series of single items assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain, and pain medication. Each item is assessed on a Likert scale from 1 (not at all) to 4 (very much).

Time frame: Up to Approximately 12 weeks

Change in from baseline at Week 12 in dyspnea items as measured by the EORTC QLQ-LC13

The EORTC QLQ-LC13 is a lung cancer specific module and consists of 13 questions assessing lung cancer-associated symptoms and treatment-related effects, including one multiple-item scale to assess dyspnea and a series of single items assessing coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain, and pain medication. Each item is assessed on a Likert scale from 1 (not at all) to 4 (very much).

Time frame: Up to Approximately 12 weeks